-
-
-
-
-
-
-
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
-
-
-
-
-
-
-
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
-
-
-
-
-
-
-
TG Therapeutics (TGTX) Reports In-Line Q3 EPS, provides product guidance
-
-
-
-
-
-
-
TG Therapeutics (TGTX) Misses Q1 EPS by 3c, Revenue Beats
-
-
-
-
-
-
-
TG Therapeutics (TGTX) Reports Prelim Q4 Results, 2024 Anticipated Milestones
-
-
-
-
-
-
-
TG Therapeutics (TGTX) Falls 45% Following Earnings, Ex-US Commercialization Agreement for BRIUMVI
-
-
-
-
-
-
-
TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

